A dietary supplement commonly used to relieve osteoarthritis and joint pain may also double as a cardioprotector, Tulane University researchers reported in The BMJ May 14.

A team funded by the National Institutes of Health has succeeded in growing human acellular vessels—implantable, bioengineered human blood vessels—to replace damaged vasculature in patients with end-stage kidney failure.

The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in mid-June to discuss recent controversies and safety practices surrounding paclitaxel-coated and -eluting medical devices, according to a notice posted April 22.

The first study to test an experimental antiplatelet compound in humans found the therapy inhibited clot formation without increasing bleeding, suggesting it could avoid that dangerous side effect of other clot-preventing drugs.

Three physicians published an editorial in Stroke proposing that tertiary healthcare centers in cities be held to stricter standards for performing endovascular thrombectomy (EVT) than their rural counterparts.

When couples attended smoking cessation programs together, their odds of quitting were nearly six times higher than for people who attempted to kick the habit alone, according to preliminary research presented April 12 at EuroPrevent 2019.